Therapeutic drug monitoring was helpful in guiding the decision‐making process for children receiving infliximab for inflammatory bowel disease. (24th August 2017)

• Record Type: Journal Article
• Authors: Deora, Vini; Kozak, Justin; El‐Kalla, Mohamed; Huynh, Hien Q.; El‐Matary, Wael
• Is Part Of: Acta pædiatrica. Volume 106:Number 11(2017)
• Page Start: 1863
• Page End: 1867
• Publication Date: 2017-08-24
• Subjects: Crohn's disease -- Inflammatory bowel disease -- Infliximab -- Therapeutic drug monitoring -- Ulcerative colitis; Pediatrics -- Periodicals; Pediatrics; 618.92
• DOI: 10.1111/apa.14008
• Languages: English
• ISSNs: 0803-5253

Abstract

Abstract: Aim: This study examined the impact of therapeutic drug monitoring (TDM) on clinical decision‐making for children receiving infliximab for inflammatory bowel disease (IBD). Methods: The medical records of children with IBD who had infliximab trough levels (ITLs) measured between January 2013 and December 2015 at two Canadian tertiary‐care centres were examined. The indications for TDM, clinical and laboratory disease activity indices and TDM‐driven treatment changes to infliximab therapy were documented. Results: We included 107 consecutive serum measurements of ITLs in 73 children (40 boys), with a median age of 16.1 years, including 52 with Crohn's disease. TDM was performed due to concerns about clinical disease activity in 24/107 (22.4%) measurements and 83 (77.6%) were ordered as routine tests. Of these, 38 (35.5%) ITLs were suboptimal (<3.5 μg/mL) and 36 (34.0%) resulted in more frequent doses of infliximab, with subsequent improvements in disease biomarkers. Interval changes were implemented as a result of 34 (32.0%) ITLs, with shorter intervals in 19 (17.0%) cases, and seven (6.5%) ITLs resulted in adding or increasing doses of immunomodulators. In addition, four children were switched to adalimumab. Conclusion: Therapeutic drug monitoring was helpful in guiding the decision‐making process for children with IBD on infliximab.